The 3 Best Bargain Stocks to Buy in Q2 2024
Best bargain stocks to buy is a simple but tricky concept. Whenever shares trade lower than an established multiple, whether that by earnings, sales, book or some other metric, there might be a rea...
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-perform...
BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
BioNTech's Q4 earnings shows a significant revenue drop and profitability concerns, with expectations of continued vaccine demand decline. Despite short-term challenges, BioNTech's mRNA technology ...
BioNTech Earnings Fall Short of Estimates. The Stock Is Down.
The pharmaceutical firm has been hit hard as demand for Covid-19 vaccines plunged.
BioNTech Q4 earnings: COVID franchise to remain a notable cash contributor in 2024
BioNTech SE (NASDAQ: BNTX) is down nearly 5.0% in premarket on Wednesday after reporting disappointing financial results for the fourth quarter. BioNTech stock down on muted guidance The stock is b...
BioNTech's stock sinks after earnings fall below expectations, hurt by writedowns of vaccine inventory
Shares of BioNTech SE BNTX, +1.22% dropped 4.4% in premarket trading Wednesday, after the Germany-based biotechnology company reported fourth-quarter results that fell sharply to miss expectations,...
After earnings plunge, BioNTech pins hopes on cancer drug launches
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, reported on Wednesday a plunge in 2023 revenue and earnings as its focus shifts towards c...
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Associat...
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA) approval...
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday,...
3 Pharma Stocks to Sell in February Before They Crash and Burn
The pharma industry has developed some real blockbusters between novel vaccines and weight loss drugs over the past few years. This has increasingly led investors to view pharma stocks as a promisi...
BioNTech SE (BNTX) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
BioNTech SE (BNTX) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics
BioNTech is diversifying its portfolio beyond its COVID-19 vaccine, focusing on antibody-drug conjugates (ADCs) and novel vaccines. The company has acquired MediLink Therapeutics' ADC technology an...
BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline
BioNTech and Pfizer's COVID-19 vaccine, COMIRNATY, generated $36.8 billion in sales in 2021, making it the highest-selling pharmaceutical product in a single year. BioNTech's stock has faced challe...
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
BioNTech's pipeline should take center stage going forward. JD.com is dirt cheap after a big sell-off.
Related Companies